Skip to main content
. 2022 Jun 21;2022(6):CD015017. doi: 10.1002/14651858.CD015017.pub3

2.8. Analysis.

2.8

Comparison 2: Ivermectin for treating COVID‐19 in outpatient settings with asymptomatic or mild disease, Outcome 8: Serious adverse events during the study period